Research Papers:
Tumortargeting Salmonella typhimurium A1R regresses an osteosarcoma in a patientderived xenograft model resistant to a moleculartargeting drug
PDF | Full Text | How to cite
Takashi Murakami1,2,3, Kentaro Igarashi1, Kei Kawaguchi1, Tasuku Kiyuna1, Yong Zhang1, Ming Zhao1, Yukihiko Hiroshima3, Scott D. Nelson5, Sarah M. Dry5, Yunfeng Li5, Jane Yanagawa6, Tara Russell6, Noah Federman7, Arun Singh4, Irmina Elliott6, Ryusei Matsuyama3, Takashi Chishima3, Kuniya Tanaka3, Itaru Endo3, Fritz C. Eilber6, Robert M. Hoffman1,2
1AntiCancer, Inc., San Diego, California, USA
2Department of Surgery, University of California, San Diego, California, USA
3Department of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan
4Division of Hematology-Oncology, University of California, Los Angeles, California, USA
5Department of Pathology, University of California Los Angeles, California, USA
6Division of Surgical Oncology, University of California, Los Angeles, California, USA
7Department of Pediatrics and Department of Orthopaedics, David Geffen School of Medicine, Mattel Children’s Hospital, UCLA’s Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California, USA
Correspondence to:
Robert M. Hoffman, email: [email protected]
Fritz C. Eilber, email: [email protected]
Keywords: osteosarcoma, nude mouse, patient-derived xenograft, Salmonella typhimurium A1-R, tumor-targeting
Received: October 20, 2016 Accepted: November 16, 2016 Published: December 20, 2016
ABSTRACT
Osteosarcoma occurs mostly in children and young adults, who are treated with multiple agents in combination with limb-salvage surgery. However, the overall 5-year survival rate for patients with recurrent or metastatic osteosarcoma is 20-30% which has not improved significantly over 30 years. Refractory patients would benefit from precise individualized therapy. We report here that a patient-derived osteosarcoma growing in a subcutaneous nude-mouse model was regressed by tumor-targeting Salmonella typhimurium A1-R (S. typhimurium A1-R, p<0.001 compared to untreated control). The osteosarcoma was only partially sensitive to the molecular-targeting drug sorafenib, which did not arrest its growth. S. typhimurium A1-R was significantly more effective than sorafenib (P <0.001). S. typhimurium grew in the treated tumors and caused extensive necrosis of the tumor tissue. These data show that S. typhimurium A1-R is powerful therapy for an osteosarcoma patient-derived xenograft model.